In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Idenix Pharmaceuticals, Inc.

http://www.idenix.com/

Latest From Idenix Pharmaceuticals, Inc.

Novo Nordisk Looks To Broaden Therapeutic Reach With Move Into ATTR

The deal leaves PRX004 in the capable hands of Novo Nordisk, which is hoping to expand beyond obesity and diabetes, while Prothena can focus on the rest of its pipeline.

Deals Research and Development Strategies

Santhera Eyes US Market Potential After DMD Candidate Tests Positive

Just under a year since Santhera restructured after disappointing late-stage clinical results with another DMD candidate, the Switzerland-headquartered company has reported positive top-line results in the condition with licensed-in vamorolone, and is planning for commercialization in late 2022/early 2023.

Clinical Trials Rare Diseases

A Dramatically Changing Landscape In Acute Myeloid Leukemia

Market Snapshot: Acute myeloid leukemia is a serious condition that affects people mainly in late middle age, for which there is a large R&D pipeline of candidate products being researched by pharmaceutical and biotech companies, many of whom are using a targeted medicine approach.

Market Snapshot Market Intelligence

Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets

Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.

Deals Business Strategies
See All

Company Information

  • Other Names / Subsidiaries
    • Novirio Pharmaceuticals Limited
UsernamePublicRestriction

Register